Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medoncare Pharmaceutical Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, which suggests a highly centralized prosecution process. Having only 1 distinct examiner means the applicant can focus on a single set of feedback and examination preferences rather than managing a diverse array of examiner behaviors.
The prosecution is concentrated within 1 distinct art unit, indicating that the subject matter is categorized within a specific technical domain. CHICKS, ASHLI ARIANA is the busiest examiner for this portfolio and is currently responsible for 1 busiest examiner pending office action. This examiner handles the only active office action currently on the docket for this applicant.
For a practitioner, the presence of 1 pending office action and 1 distinct examiner simplifies the strategic approach. The focus is entirely on the 1 pending office action and the specific requirements of the 1 distinct art unit. By understanding the tendencies of CHICKS, ASHLI ARIANA, the applicant can more effectively navigate the prosecution of the single active matter in the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHICKS, ASHLI ARIANA | 1 | 60.0% | +51.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713580 | PHARMACEUTICAL COMPOSITION CONTAINING PLATINUM DRUGS OR PLATINUM DRUG COCRYSTALS, AND USE THEREOF | CHICKS, ASHLI ARIANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713580 | PHARMACEUTICAL COMPOSITION CONTAINING PLATINUM DRUGS OR PLATINUM DRUG COCRYSTALS, AND USE THEREOF | CHICKS, ASHLI ARIANA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713580 | PHARMACEUTICAL COMPOSITION CONTAINING PLATINUM DRUGS OR PLATINUM DRUG COCRYSTALS, AND USE THEREOF | CHICKS, ASHLI ARIANA | 1626 | §103§112 | Non-Final OA | — | Pending | May 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedoncare Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ashli Ariana Chicks has the most, with 1 of Medoncare Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
